Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN PLASTIC CONTAINER vs TRAVASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Travasol 10% (amino acids injection) provides essential and non-essential amino acids for protein synthesis and nitrogen equilibrium in patients unable to obtain adequate nutrition orally or enterally. Amino acids are building blocks for proteins; they also serve as substrates for gluconeogenesis and other metabolic pathways.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
Intravenous infusion: 500 mL to 2 L per day, administered at a rate not exceeding 4 mL/kg/h. Typical adult dose is 1-2 g protein/kg/day (equivalent to 10-20 mL/kg/day of 10% solution). Rate and volume are adjusted based on patient's metabolic needs and clinical status.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Not applicable as a single entity; constituent amino acids have half-lives varying from minutes to hours (e.g., 10-30 min for most). Clinical context: continuous infusion maintains steady state.
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Renal excretion of infused amino acids and their metabolites; excess nitrogen excreted as urea in urine. ~90-95% of infused amino acids are utilized or excreted renally. Fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution